MGX - Utang jangka dawa Metagenomi Therapeutics

This daily chart of Metagenomi, Inc. (MGX) long-term liability values is fixed at 0.03. Metagenomi, Inc. (MGX) acts as a pioneer in precision genome editing, investing heavily in the discovery of new CRISPR systems. The business relies on the synergy of artificial intelligence and digital libraries to develop therapies. High-tech laboratories and screening capacities operate at optimal efficiency, ensuring high-quality DNA modification.

Long-term debt measures the total credit obligations with a maturity of more than one year, allowing an investor to assess capital stability and the issuer's solvency regardless of market volatility. By analyzing the long-term debt structure of the enterprise on GURU.Markets, one can monitor the financial leverage of Metagenomi, Inc. (MGX), which is critical when self-funding the development of DNA editing systems under resource-constrained conditions.